glp 1 crackdown FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Enforcement on Compounded GLP-1

Changes range from acute inflammatory cell infiltrate(s) or occasional aggregates of lymphocytes/lymphohistiocytic cells/foci of mononuclear cells without associated alterations of adjacent hepatocytes, to large panlobular patches of distinct hepatocyte necrosis accompanied by polymorphonuclear and mononuclear (lymphocytes, plasma cells, macrophages) cellular infiltrates

These findings reinforce previous studies while also highlighting the therapeutic potential of GLP-1 RAs in dermatology and the need for ongoing attention to cutaneous safety and mechanism-based stratification of patients

Arisi et al., 2002)

Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1